Peripheral T cell lymphomas (PTCLs) are a heterogeneous and poorly understood group of non-Hodgkin lymphomas 1,2 .
Here we combined whole-exome sequencing of 12 tumor-normal DNA pairs, RNA sequencing analysis and targeted deep sequencing to identify new genetic alterations in PTCL transformation. These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples. Mechanistically, the RHOA Gly17Val protein interferes with RHOA signaling in biochemical and cellular assays, an effect potentially mediated by the sequestration of activated guanine-exchange factor (GEF) proteins. In addition, we describe new and recurrent, albeit less frequent, genetic defects including mutations in FYN, ATM, B2M and CD58 implicating SRC signaling, impaired DNA damage response and escape from immune surveillance mechanisms in the pathogenesis of PTCL.
To investigate the genetic and pathogenic mechanisms of aggressive PTCLs, we performed whole-exome sequencing of matched tumor and normal DNA samples from 12 individuals with PTCL, including 6 PTCL-NOS cases, 3 AITL cases, 2 nasal-type NK/T cell lymphoma cases and 1 enteropathy-associated T cell lymphoma (Supplementary  Tables 1 and 2 ). This analysis identified a mean of 24 nonsynonymous somatic mutations per sample (range of 4-57) (Supplementary Table 1) . A total of 288 candidate coding somatic mutations in 268 genes were identified. These candidates included five mutant alleles in the TET2 tumor suppressor gene, three mutant alleles in the SETD2 and DNAH5 genes and two mutant alleles in the TACC2, RYR3, PTPRD and MGAT4C genes (Supplementary Tables 3 and 4 ). In addition, we identified a recurrent heterozygous mutation in the RHOA small GTPase gene (NM_001664; encoding a p.Gly17Val alteration) present in two independent AITLs and one PTCL-NOS sample ( Fig. 1a and Supplementary Tables 3 and 4) . These results were confirmed and extended by deep sequencing analysis of 125 PTCL DNA samples, which showed the presence of the recurrent RHOA mutation encoding p.Gly17Val and detected several additional RHOA mutations (encoding p.Cys16Arg, p.Thr19Ile, p.Gly17Glu and p.Asp120Tyr) present in a single case each ( Fig. 1a and Supplementary Table 5) . Notably, the frequency of the allele encoding the p.Gly17Val alteration correlated with the proportion of tumor cells in PTCL biopsies, as evaluated by multicolor flow cytometry (Supplementary Fig. 1 ), supporting the idea that the variable and frequently low proportion of reads harboring this mutation in many PTCLs might primarily result from the low tumor content in these samples. Thus, to best assess the actual prevalence of the RHOA mutation encoding p.Gly17Val in our series, we reanalyzed this panel using a highly sensitive (1:1,000) allele-specific PCR mutation assay. Using this approach, we detected the presence of the allele encoding mutant Gly17Val RHOA in 30 samples, including 22 of 35 (67%) AITLs and 8 of 44 (18%) PTCL-NOS tumors (AITL versus all other PTCLs, P < 0.001; PTCL-NOS versus non-AITL, non-PTCL-NOS tumors, P < 0.002; AITL versus PTCL-NOS tumors, P < 0.001) (Fig. 1b,c,  Supplementary Fig. 2 and Supplementary Table 6 ).
RHOA belongs to the Rho family of small GTPases, a group of Ras-like proteins responsible for linking a variety of cell surface receptors to different intracellular signaling proteins [3] [4] [5] . As is the case for RAS and most other small GTPases, RHOA cycles between an inactive, GDP-bound configuration and an active, GTP-bound configuration 4, 5 , representing a molecular switch that is strictly controlled by the GTPloading activity of GEF proteins 4, 5 . In its active configuration, GTP-bound RHOA interacts with multiple downstream effectors that control the structure and dynamics of the actin cytoskeleton and the formation of stress fibers 6 . Given the recurrent nature of the RHOA mutation encoding p.Gly17Val, we postulated that this allele could represent a gain-of-function mutation with either constitutively active or dominant-negative activity.
The RHO family of GTPases, including RHOA, regulates the actin cytoskeleton and cell adhesion and is implicated in cell polarization in multiple cell types 6, 7 . Thus, to explore the functional effects of RHOA Gly17Val, we analyzed changes in fibroblast cell morphology induced by the expression of GFP-fused wild-type RHOA, constitutively active RHOA Gln63Leu [8] [9] [10] [11] , dominant-negative RHOA Thr19Asn [10] [11] [12] and RHOA Gly17Val. Activation of RHOA signaling triggered by the overexpression of GFP-fused RHOA and, most prominently, by the expression of GFP-fused constitutively active RHOA Gln63Leu induced loss of adhesion and round cell morphology in HEK293T cells (Fig. 2a) . In contrast, cells expressing GFP-fused RHOA Gly17Val mimicked the phenotype of fibroblasts expressing GFP-fused dominant negative RHOA Thr19Asn, showing elongated morphology and increased number of cellular protrusions (Fig. 2a) . Similarly, immunofluorescence analysis of F-actin in HeLa cells showed increased stress fiber formation in cells expressing GFP-fused wild-type RHOA, which was markedly accentuated upon constitutive activation of RHOA signaling triggered by expression of the GFP-fused RHOA Gln63Leu mutant (Fig. 2b) . In contrast, cells expressing GFP-fused RHOA Gly17Val or RHOA Thr19Asn showed decreased numbers of F-actin stress fibers, which is consistent with an inhibitory role of these mutants in RHO signaling (Fig. 2b) . 
Following on these results, we expressed HA-tagged forms of wildtype RHOA and RHOA Gly17Val in Jurkat T cells and tested their ability to interact with rhotekin, an effector protein that specifically recognizes the active, GTP-bound form of RHOA 13 . Rhotekin pulldown analysis showed activation of HA-RHOA in Jurkat cells under basal conditions, and activity was further increased with serum stimulation (Fig. 2c) . In contrast, rhotekin did not interact with HA-tagged RHOA Gly17Val (Fig. 2c) . Similarly, rhotekin did not interact with dominant-negative RHOA Thr19Asn, whereas the constitutively active RHOA Gln63Leu protein showed a marked increase in rhotekin binding (Fig. 2c) . Given that rhotekin selectively binds to the GTP-bound form of RHOA, we hypothesized that RHOA Gly17Val is locked in an inactive configuration devoid of GTP. Indeed, a highly related RHOA Gly17Ala mutant capable of interacting with GEF proteins with high affinity but resistant to GEF-induced GTP loading and activation has been described 14 . To test our hypothesis, we analyzed the ability of GST-fused RHOA, RHOA Gly17Val and RHOA Gly17Ala recombinant proteins to bind to GTP in response to MCF2L GEF stimulation in vitro using a fluorescence polarization assay. As expected, MCF2L triggered loading of a fluorescent GTP analog (mant-GTP) onto GST-RHOA (Fig. 2d) . However, GST-fused RHOA Gly17Ala and RHOA Gly17Val were resistant to the activity of this GEF (Fig. 2d ). Finally, we tested whether RHOA Gly17Val could function as a high-affinity GEF trap analogous to RHOA Gly17Ala, sequestering activated GEF proteins in T cells. GST pulldown assays against ARHGEF1, a GEF that is highly expressed in T cells, showed increased affinity for RHOA Gly17Val and, most markedly, for RHOA Gly17Ala compared to wild-type RHOA (Fig. 2e) . Overall, these results are consistent with an inhibitory role for RHOA Gly17Val in RHO signaling, potentially mediated by the sequestration of GEF proteins, and support a role for the disruption of RHOA signaling in the pathogenesis of PTCLs.
Next, to more broadly assess the presence of recurrent genetic alterations and fusion oncogenes in PTCL, we analyzed a cohort of 34 lymphoma samples by RNA sequencing (RNA-seq) (Supplementary Table 7 ). This analysis identified four samples harboring ALK fusion transcripts (three NPM1-ALK and one TFG-ALK), all corresponding to ALCL cases (Supplementary Table 8 ). In addition, we detected the presence of candidate recurrent mutations in TET2, DNMT3A and IDH2 and identified additional potential drivers of PTCL transformation (Supplementary Table 9 ). Deep sequencing analysis of these and additional selected candidate genes, including FYN, TET3, CDKN2A, PRKD2, RHOT2, SMARCAL1, ATM, B2M and CD58, in an extended panel of 125 PTCL DNA samples, including those analyzed by RNA-seq, showed a prominent role for mutations targeting genes involved in DNA methylation and hydroxymethylation (TET2, DNMT3A, IDH2 and TET3; Fig. 3a and Supplementary Table 5), as shown before [15] [16] [17] , and highlighted the role of defective DNA damage response (ATM) and escape from T cell and NK cell immune surveillance (B2M and CD58) in the pathogenesis of PTCL ( Fig. 3b and Supplementary Table 5 ). In addition, we detected the presence of new recurrent FYN kinase (NM_002037) mutations, including a recurrent allele encoding a p.Arg176Cys substitution present in two PTCL-NOS cases and a mutation encoding a p.Leu174Arg alteration found in one AITL sample, in addition to the p.Tyr531His-encoding allele identified via exome analysis in a PTCL-NOS sample, for an overall frequency of 3% (4/137) for FYN mutations in our series ( Fig. 3b and Supplementary Table 5 ).
The FYN tyrosine kinase is, along with LCK, the predominant SRC family kinase found in T lymphocytes and has an important role in T cell activation upon T cell receptor (TCR) stimulation 18 . Strikingly, FYN mutations found in PTCL are predicted to specifically disrupt the intramolecular inhibitory interaction of the FYN SH2 domain with the C-terminal SRC kinase (CSK)-phosphorylated Tyr531 residue. Consistently, expression of FYN Leu174Arg, FYN Arg176Cys and FYN Tyr531His in Rat1A rat embryo fibroblast cells resulted in increased levels of FYN activation compared with control cells expressing wild-type FYN (Fig. 4a,b) . In addition, structural model analysis of wild-type and mutant FYN proteins further supported this hypothesis (Fig. 4c,d) . To test this model, we analyzed the interaction between recombinant GST-fused FYN SH2 domain and biotinylated C-terminal FYN peptides encompassing position Tyr531. In these assays, wild-type FYN SH2 domain was effectively pulled down with the phosphopeptide with Tyr531 phosphorylated but not with the corresponding unphosphorylated sequence or with a peptide containing a p.Tyr531His substitution (Fig. 4e) npg l e t t e r s Tyr531 (Fig. 4f) . Consistently, CSK effectively inhibited wild-type FYN but did not abrogate the activity of the mutant FYN proteins (Fig. 4g) . Finally, given the prominent role of kinase inhibitors as targeted therapies for tumors driven by constitutively active kinase oncogenes, we tested the ability of dasatinib, a multikinase inhibitor that blocks ABL1 and SRC kinases 19 , to inhibit the activity of FYN Leu174Arg, FYN Arg176Cys and FYN Tyr531His mutant proteins. Notably, in each case, dasatinib treatment induced dose-dependent inhibition of FYN phosphorylation (Fig. 4h) . Moreover, dasatinib treatment impaired the growth of transformed Rat1A cells expressing the FYN Tyr531His mutant protein but not that of cells expressing a drugresistant gatekeeper mutant of this kinase (FYN Thr342Ile/Tyr531His) (Fig. 4i,j) . On the basis of these results, we propose that SRC kinase inhibition with dasatinib may confer therapeutic benefit in selected PTCL cases harboring activating mutations in the FYN kinase gene.
URLs. Primer3, http://primer3plus.com/cgi-bin/dev/primer3plus.cgi; BWA-MEM, http://bio-bwa.sourceforge.net/.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Exome data and RNA-seq data are available in dbGaP (access code phs000689.v1.p1). 
ONLINE METHODS
Patient samples. DNA samples from PTCLs were provided by tumor banks at the Columbia University Medical Center (New York, New York, USA), the Sylvester Comprehensive Cancer Center (Miami, Florida, USA), the Hospital Central de Asturias (Oviedo, Spain), the Centro Nacional de Investigaciones Oncologicas (Madrid, Spain), the Institut Gustave Roussy (Villejuif, France), the Centre Henri Becquerel (Rouen, France) and Hospital Clinic (Barcelona, Spain). Samples were obtained with informed consent, and analysis was conducted under the supervision of the Columbia University Medical Center Institutional Review Board. We selected samples for wholeexome sequencing on the basis of the availability of sufficient DNA from diagnosis and normal (blood, buccal swab or non-tumor infiltrated biopsy material) matched samples.
Whole-exome capture and next-generation sequence analysis. We used matched tumor and normal DNA samples from 12 individuals with PTCL (Supplementary Table 1 ) for exome capture with the SureSelect 50Mb All Exon kit (Agilent Technologies), following standard protocols. We performed paired-end sequencing (2 × 100 bp) using HiSeq 2000 sequencing instruments at Centrillion Biosciences (Palo Alto, California, USA). Illumina HiSeq analysis produced between 67.5 and 136.8 million paired-end reads per sample (Supplementary Table 2 ). We mapped reads to the hg19 reference genome using the Burrows-Wheeler Aligner (BWA) alignment tool version 0.5.9. Mean depth (defined as the mean number of reads covering the captured coding sequence of a haploid reference) was 45×, with 84% of the genome covered by more than 10× and 58% of the genome covered by more than 30×. We identified sites that differed from the reference (called here variants) in each sample independently. We constructed empirical priors for the distribution of variant frequencies for each sample. We obtained high-credibility intervals (posterior probability ≥ 1-10 −5 ) for the corresponding change in frequency between tumor and normal samples, using the SAVI algorithm (Statistical Algorithm for Variant Identification) developed at Columbia University 20, 21 . There were 18,000 germline SNPs in the coding region, comparable to the numbers of SNPs detected in previous reports 20 . Most of the candidate germline SNPs (16,000 or ~90% of germline variants) were reported in the dbSNP database. We identified candidate somatic variants using the following criteria: variant total depth in tumor and normal greater than 10× and less than 300×, variant frequency greater than 15% in tumor samples and less than 3% in normal samples, and at least 1% change in frequency from normal samples with high posterior probability (≥1-10 −5 ). To remove systematic errors, we excluded all variants that were found to be present in any of the normal samples. In addition, to eliminate ambiguous mapping from captured pseudogenes and regions of low complexity, each variant with a flanking 20-base context sequence around its genomic position was mapped to the hg19 reference genome using the BLAST algorithm. We retained only the variants with unique mappability, i.e., we required the 41-base sequence to uniquely map to the reference genome, with only one mismatch.
Mutation validation.
We designed primers flanking exons containing 121 randomly selected candidate somatic variants identified by exome sequencing using Primer3 and used whole genome-amplified DNA from tumor and matched normal DNA samples for PCR amplification. We analyzed the resulting amplicons by direct bidirectional dideoxynucleotide sequencing and obtained a validation rate of 90% (Supplementary Table 1 Table 7) . We obtained on average over 67.6 million reads, 51.5 million (75.7%) of which mapped to the human NCBI reference sequence (RefSeq) database using BWA alignment algorithms 22 . Reads mapping to the same starting position were discarded. We identified sites that differed from the reference in each sample and constructed empirical priors for the distribution of variant frequencies for each sample independently. To reduce the false positive rate in variant detection and remove mapping artifacts and systematic errors, we mapped paired-end reads for the samples to human RefSeq with the Bowtie 2 alignment algorithm 23 , which mapped a total of 1.83 billion reads (76%) properly to the reference. We then identified sites that differed from the reference in each sample and intersected the set of variants identified with both BWA and Bowtie 2 alignment as previously described 24 . In all samples, we selected variants with total depth of >10× and frequency of >20% and excluded variants identified in the dbSNP135 database, as well as those that did not pass the Multiplicity filter. In addition, variants corresponding to poorly expressed (< 3 reads per kilobase per million) genes were removed to reduce the effects of spurious PCR amplification during library preparation. To reduce the presence of germline mutations, identified variants that were also present in 65 DNA sequencing samples from unaffected individuals were excluded, and we also removed variants common to those present in 11 RNA-seq samples from normal B and T cells. In detail, we mapped normal RNA-seq sample reads with BWA and Bowtie 2 to human RefSeq and identified variants, creating an internal normal variant database (INVD) composed of the union of all the variants identified in normal B and T cells. Successively, we filtered out variants occurring in PTCL samples that overlapped with the INVD variants. Finally, we limited the list of variants to those identified in genes found to be somatically mutated in PTCL by exome sequencing.
Targeted deep resequencing.
Mutational analysis of selected genes of interest was performed by targeted resequencing using microfluidics PCR (Access Array system, Fluidigm) followed by sequencing of the amplicon libraries on a MiSeq instrument (Illumina). Primers targeting the regions of interest were designed at Fluidigm to produce amplicons of 200 ± 20 bp. We performed multiplex PCR amplification of up to ten amplicons per well of the Fluidigm Access Array chip according to the manufacturer's instructions, using 30 ng of DNA per sample. After multiplex PCR amplification, resulting DNA products were barcoded so that all amplicons corresponding to each sample carried the same index. Indexed libraries were pooled, and the resulting library was quantified by quantitative PCR using the Kapa Library Quantification kit (Kapa Biosystems) on a 7500 PCR instrument (Applied Biosystems). Amplicon libraries were spiked with ~25% PhiX genomic library to increase amplicon diversity and were sequenced on a MiSeq instrument to generate 2 × 251-bp paired reads, following an amplicon sequencing protocol for custom primers. Each pair of paired-end reads produced by MiSeq was stitched together using FLASH version 1.2.6 (Fast Length Adjustment of SHort reads), given that the amplicon sequences (up to 200 bp) were shorter than the read length (251 bp). This step increased the quality of the reads, correcting for mismatches in overlap by selecting the base with higher quality. Then, 5′ and 3′ adaptors and PCR primer sequences were trimmed using cutadapt. Merged and trimmed reads were aligned to the UCSC hg19 reference genome as single-end reads using BWA-MEM. Aligned reads were analyzed for variants using the SAVI algorithm, and variants were selected on the basis of coverage depth and frequency. Given the presence of abundant normal cells in most PTCL samples, variants with a frequency of around 50% were flagged as candidate private germline SNPs. Candidate variants identified by this first round of amplicon resequencing were independently validated in a second round of targeted deep sequencing. Briefly, we selectively amplified the amplicons covering the positions of candidate mutations in their corresponding positive samples, barcoded these PCR products, pooled them and sequenced the resulting library on a MiSeq instrument.
RNA sequencing gene fusion analysis. We performed gene fusion analysis on RNA-seq data using the ChimeraScan 25 and deFuse 26 algorithms, which identify gene fusion candidates by detecting read pairs discordantly mapping to two different genes. From this analysis, we then successively reduced the candidate list by applying homology-based filters and by detecting reads spanning junction breakpoints (split reads). Finally, we annotated candidate fusions on the basis of the breakpoint coordinates, predicted amino acid sequences, ORF conservation and UniProt database proteomic information.
Quantitative RHOA p.Gly17Val allele-specific qPCR assays. Analysis and quantitation of the RHOA allele encoding p.Gly17Val was performed using Mutation Detection Assay Competitive Allele-Specific TaqMan PCR (Life Technologies), following the manufacturer's instructions with slight npg modifications. All analyses were conducted on a 7500 RT-PCR system run with 7500 software (v.2.0.6, Applied Biosystems). Assays were run in 96-well plates in a reaction volume of 20 µl, using 50 ng of genomic DNA, 10 µl of TaqMan Universal PCR Master Mix 2× and 2 µl of specific TaqMan assay 10× (RHOA wild-type allele or encoding p.Gly17Val). We used a thermal profile of 10 min at 95 °C for Hot Gold Start activation followed by 40 cycles of amplification (95 °C for 15 s and 55 °C for 60 s). The threshold for detection was set at 0.05. Standard curves of C t versus log template amount for each specific assay were linear over the range of 25 to 250,000 copies of plasmid DNA. We determined a sensitivity of detection for the mutant RHOA allele encoding p.Gly17Val assay of <0.1% by analyzing samples consisting of 10, 25, 100 and 1,000 copies of the DNA plasmid encoding mutant RHOA allele p.Gly17Val spiked into 30 ng (10,000 copies) of wild-type genomic DNA, which corresponded to samples containing 0.1%, 0.25%, 1% or 10% mutation load, respectively. Data analysis was performed with Mutation Detector Software (Life Technologies). Briefly, in mutation analysis calculations, the difference between the C t value of the mutant allele assay and the C t value of the wild-type allele assay was calculated for all mutant allele assays run on the sample. This ∆C t value represents the quantity of the specific mutant allele detected in the sample and was used to determine sample mutation status by comparison to a predetermined detection ∆C t cutoff value.
Structural depiction and analysis. We identified structural coverage of the FYN protein through use of the PSI-Blast and SKAN algorithms. The structures 2DQ7, 2DLY, 3UA7, 2LP5 and 1G83 were structurally aligned into composite structures to assess conformational flexibilities and subsequently analyzed through use of the Chimera Suite 27, 28 . In silico modeling of identified mutations was performed using the I-TASSER software suite and Modeller program; structures were refined and analyzed in Chimera 27, 29 . We predicted protein stability changes upon mutation through use of the SDM potential energy statistical algorithm and associated software 30 . We created all structural images using UCSF Chimera 27 .
Plasmids and vectors.
We obtained pcDNA3 EGFP-RHOA WT (plasmid 12965) containing the full-length human RHOA construct fused to EGFP as well as pcDNA3 EGFP-RHOA Thr19Asn dominant negative (plasmid 12967) and pcDNA3-EGFP-RHOA Gln63Leu constitutively active (plasmid 12968) mutants from Addgene 31 . We generated the RHOA allele encoding p.Gly17Val by site-directed mutagenesis on the mammalian expression vector pcDNA3-EGFP-RHOA WT using the QuikChange II XL Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's instructions. We cloned PCR products encompassing wild-type RHOA and encoding RHOA p.Gly17Val, RHOA p.Thr19Asn and RHOA p.Gln63Leu with an N-terminal HA tag as BglII-XhoI fragments into the pMSCV vector for retroviral expression. We obtained pRK5-c-FYN plasmid containing a full-length FYN ORF 32 from Addgene (plasmid 16032), subcloned the FYN ORF in the pcDNA3.1 plasmid vector and introduced the mutations in FYN encoding FYN p.Leu174Arg, FYN p.Arg176Cys, FYN p.Tyr531His and FYN p.Thr342Ile/Tyr531His using the QuikChange II XL Site-Directed Mutagenesis kit. All constructs were verified by sequencing. Wild-type and mutant FYN cDNA encoding an N-terminal HA tag was subcloned into pcDNA3.1(−) and inserted into the MSCV240-puromycine-IRES-GFP retroviral vector. The CSK-pcDNA3.1 (+) hygro plasmid containing a full-length CSK ORF was a gift from X.-Y. Huang (Cornell University). We cloned FYN SH2 domain complementary DNA constructs encoding wild-type FYN SH2 domain (codons 148-231) with an N-terminal GST tag in the pGEX4-T1 expression vector between the EcoRI and XhoI restriction sites. We generated the FYN SH2 domain mutations encoding p.Leu174Arg and p.Arg176Cys by site-directed mutagenesis on the Escherichia coli expression pGEX4-T1 vector encoding the FYN SH2 domain using the QuikChange II XL Site-Directed Mutagenesis kit according to the manufacturer's instructions. cleared protein lysate with 20 µl of rhotekin RBD beads (Cystoskeleton) for 1 h at 4 °C with rotation. After incubation, rhotekin RBD beads were washed with 500 µl of wash buffer (25 mM Tris, pH 7.5, 30 mM MgCl 2 and 40 mM NaCl) and resuspended in 15 µl of SDS-PAGE loading buffer. Rhotekin bead samples were loaded into a Bis-Tris gel, and proteins were resolved by electrophoresis in MES buffer and transferred to a PVDF membrane. The presence of HA-tagged activated RHOA associated with the rhotekin RBD beads was determined by immunoblotting with an antibody to HA following standard procedures.
Immunoprecipitation and protein blot analysis of FYN activation. We performed FYN immunoprecipitations in Rat1A cells infected with control (empty vector) retroviruses or with retroviruses expressing wild-type FYN, FYN Leu174Arg, FYN Arg176Cys or FYN Tyr531His using FYN rabbit polyclonal antibody (4023, Cell Signaling Technology) 33 at 1:100 dilution and analyzed FYN phosphorylation via protein blot analysis with a Phospho-Src Family (Tyr416) polyclonal antibody (2101, Cell Signaling Technology) at 1:100 dilution.
FYN protein expression in E. coli, purification, and peptide binding assays. We expressed wild-type and mutant FYN SH2 domain as GST-fused proteins in E. coli Rosetta 2(DE3) cells as detailed for the production of GST-RHOA fusion proteins. Next, we performed peptide binding assays with the Pull-Down Biotinylated Protein-protein Interaction kit (Thermo Scientific), according to the manufacturer's instructions, using a biotinylated FYN peptide corresponding to amino acids 527-537 (biotin-TEPQYQPGENL), a biotinylated FYN peptide corresponding to amino acids 527-537 with phosphorylation at Tyr531 (biotin-TEPQpYQPGENL) and a biotinylated FYN peptide corresponding to amino acids 527-537 with a p.Tyr51His alteration (biotin-TEPQHQPGENL) (Anaspec). Briefly, we incubated synthetic biotinylated peptides with purified GST-fused FYN SH2 domain or mutant FYN SH2 domain or with GST alone for 1 h at 4 °C, resolved and analyzed interacting proteins via 10% SDS-PAGE, transferred proteins to a PVDF membrane and carried out protein blot analysis with an antibody to GST. Cell proliferation assays. We analyzed relative cell growth at 72 h in vehicletreated and dasatinib-treated (1 µM) Rat1A transformed cells expressing either the FYN Tyr531His mutant or a FYN Thr342Ile/Tyr531His double mutant. Cell growth was determined in triplicate by measurement of metabolic reduction of the tetrazolium salt MTT using Cell Proliferation Kit I (Roche) according to the manufacturer's instructions.
Statistical analyses. We evaluated differences in the percentage of wild type and Gly17Val RHOA in different PTCL groups using Fisher's exact test. We analyzed differences in cell growth rate in control and dasatinib-treated cells using Student's t test. We tested the linear correlation between tumor content in PTCL samples and burden for the RHOA allele encoding p.Gly17Val with the coefficient of determination R 2 .
